StreetInsider.com News Articles

Better Hearing and Whole-Body Health: What to Know About MRI Access with Cochlear Implants

Fri, 29 May 2026 14:13:00 -0400

During Better Hearing and Speech Month, understanding MRI compatibility is an important part of long-term hearing care

LONE TREE, Colo., May 29, 2026 /PRNewswire/ -- May is Better Hearing and Speech Month, a month dedicated to raising awareness about the importance of hearing health. For the millions of people who experience hearing loss in the US, this month serves as a reminder that better hearing is not just about improved communication, it is a critical component of comprehensive health and wellbeing.

Better Hearing and Whole-Body Health: What to Know About MRI Access with Cochlear Implants

Fri, 29 May 2026 14:13:00 -0400

During Better Hearing and Speech Month, understanding MRI compatibility is an important part of long-term hearing care

Better Hearing and Whole-Body Health: What to Know About MRI Access with Cochlear Implants

Fri, 29 May 2026 14:13:00 -0400

During Better Hearing and Speech Month, understanding MRI compatibility is an important part of long-term hearing care

Better Hearing and Whole-Body Health: What to Know About MRI Access with Cochlear Implants

Fri, 29 May 2026 14:13:00 -0400

During Better Hearing and Speech Month, understanding MRI compatibility is an important part of long-term hearing care

Better Hearing and Whole-Body Health: What to Know About MRI Access with Cochlear Implants

Fri, 29 May 2026 14:13:00 -0400

During Better Hearing and Speech Month, understanding MRI compatibility is an important part of long-term hearing care

Better Hearing and Whole-Body Health: What to Know About MRI Access with Cochlear Implants

Fri, 29 May 2026 14:13:00 -0400

During Better Hearing and Speech Month, understanding MRI compatibility is an important part of long-term hearing care

JPMorgan Starts Cochlear Ltd. (COH:AU) (CHEOY) at Neutral

Thu, 16 Apr 2026 02:52:44 -0400

(Updated - April 16, 2026 2:52 AM EDT)

JPMorgan analyst Chris Cooper initiates coverage on Cochlear Ltd. (COH:AU) (OTC: CHEOY) with a Neutral rating and a price target of AUD187.90.

The analyst comments: "At 26x NTM P/E, COH is trading -38% below its 10-year average of 42x. However, relative to growth, a PEG of 3.5x is not compelling given the degree of macro/execution and recent track record of delivery versus market expectations (sector PEG 1.5x/market PEG 2.3x). COH has missed consensus revenue forecasts for each of the last four half-year cycles, and this has driven pronounced reactions in a stock that should

JPMorgan Starts Cochlear Ltd. (COH:AU) (CHEOY) at Neutral

Thu, 16 Apr 2026 02:52:44 -0400

(Updated - April 16, 2026 2:52 AM EDT)

JPMorgan analyst Chris Cooper initiates coverage on Cochlear Ltd. (COH:AU) (OTC: CHEOY) with a Neutral rating and a price target of AUD187.90.

JPMorgan Starts Cochlear Ltd. (COH:AU) (CHEOY) at Neutral

Thu, 16 Apr 2026 02:52:44 -0400

(Updated - April 16, 2026 2:52 AM EDT)

JPMorgan analyst Chris Cooper initiates coverage on Cochlear Ltd. (COH:AU) (OTC: CHEOY) with a Neutral rating and a price target of AUD187.90.

JPMorgan Starts Cochlear Ltd. (COH:AU) (CHEOY) at Neutral

Thu, 16 Apr 2026 02:52:44 -0400

(Updated - April 16, 2026 2:52 AM EDT)

JPMorgan analyst Chris Cooper initiates coverage on Cochlear Ltd. (COH:AU) (OTC: CHEOY) with a Neutral rating and a price target of AUD187.90.

JPMorgan Starts Cochlear Ltd. (COH:AU) (CHEOY) at Neutral

Thu, 16 Apr 2026 02:52:44 -0400

(Updated - April 16, 2026 2:52 AM EDT)

JPMorgan analyst Chris Cooper initiates coverage on Cochlear Ltd. (COH:AU) (OTC: CHEOY) with a Neutral rating and a price target of AUD187.90.

JPMorgan Starts Cochlear Ltd. (COH:AU) (CHEOY) at Neutral

Thu, 16 Apr 2026 02:52:44 -0400

(Updated - April 16, 2026 2:52 AM EDT)

JPMorgan analyst Chris Cooper initiates coverage on Cochlear Ltd. (COH:AU) (OTC: CHEOY) with a Neutral rating and a price target of AUD187.90.

Cochlear Ltd. (COH:AU) (CHEOY) PT Lowered to AUD215.80 at Goldman Sachs

Fri, 13 Mar 2026 09:51:28 -0400

Goldman Sachs analyst Davin Thillainathan lowered the price target on Cochlear Ltd. (COH:AU) (OTC: CHEOY) to AUD215.80 (from AUD244.90) while maintaining a Neutral rating.

Cochlear Ltd. (COH:AU) (CHEOY) PT Lowered to AUD215.80 at Goldman Sachs

Fri, 13 Mar 2026 09:51:28 -0400

Goldman Sachs analyst Davin Thillainathan lowered the price target on Cochlear Ltd. (COH:AU) (OTC: CHEOY) to AUD215.80 (from AUD244.90) while maintaining a Neutral rating.

Cochlear Ltd. (COH:AU) (CHEOY) PT Lowered to AUD215.80 at Goldman Sachs

Fri, 13 Mar 2026 09:51:28 -0400

Goldman Sachs analyst Davin Thillainathan lowered the price target on Cochlear Ltd. (COH:AU) (OTC: CHEOY) to AUD215.80 (from AUD244.90) while maintaining a Neutral rating.

Cochlear Ltd. (COH:AU) (CHEOY) PT Lowered to AUD215.80 at Goldman Sachs

Fri, 13 Mar 2026 09:51:28 -0400

Goldman Sachs analyst Davin Thillainathan lowered the price target on Cochlear Ltd. (COH:AU) (OTC: CHEOY) to AUD215.80 (from AUD244.90) while maintaining a Neutral rating.

BofA Securities Upgrades Cochlear Ltd. (COH:AU) (CHEOY) to Buy

Mon, 09 Mar 2026 07:19:15 -0400